跳至主要内容
临床试验/NCT00408135
NCT00408135已完成3 期

Evaluation of the Safety, Efficacy and Acceptability of HMR 3647 (20% Fine Granules 1 g Sachet) in Children With Infections

Sanofi1 个研究点 分布在 1 个国家目标入组 111 人开始时间: 2004年8月最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
Sanofi
入组人数
111
试验地点
1
主要终点
Safety evaluation: presence/absence of subjective/objective symptoms and abnormal laboratory findings (abnormal changes of parameters in general hematological tests and blood biochemical tests).

研究概览

简要总结

The primary objective is to assess the safety of telithromycin (HMR 3647) (20% fine granules) 1g filling sachet in children with infections (Respiratory tract infections, Dermatological infections, Otorhinolaryngological infections, Dentistry/Oral surgery infections).

Secondary objectives are to assess the clinical efficacy, bacteriological efficacy and acceptability of telithromycin (20% fine granules) 1g filling sachet in children with infections.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Months 至 16 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Outpatients of weight from 7.0 kg.
  • For respiratory tract infections:subjects diagnosed with mild or moderate respiratory tract infection (excluding pneumonia) based on a fever (≥ 38°C) or C-Reactive Protein positive, clinical symptoms/signs, and laboratory findings.
  • For dermatological infections: subjects diagnosed with mild or moderate dermatological infection in terms of clinical symptoms/signs and laboratory findings.
  • For otorhinolaryngological infections:subjects with purulent / mucopurulent rhinorrhea and postrhinorrhea, subjects diagnosed with mild or moderate otorhinolaryngological infection in terms of clinical symptoms/signs and laboratory findings
  • For dental / oral surgical infections: subjects who have formed obstructive abscess and diagnosed with mild or moderate dental / oral surgical infection

排除标准

  • 未提供

结局指标

主要结局

Safety evaluation: presence/absence of subjective/objective symptoms and abnormal laboratory findings (abnormal changes of parameters in general hematological tests and blood biochemical tests).

次要结局

  • Clinical efficacy:change in the symptoms and signs at end of therapy visit and at the test of cure visit

研究者

发起方
Sanofi
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验